🇺🇸 FDA
Pipeline program

VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX

LOXO-BTK-20022

Phase 3 small_molecule active

Quick answer

VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) is a Phase 3 program (small_molecule) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
Ology Bioservices Ireland LTD
Indication
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials